Abstract
In this study the effect of suramin on tumor growth, vascularity and oxygenation of a human glioma xenografted in the nude mouse was examined. Vascular parameters and oxygenation status of the xenografts were determined immunohistochemically in frozen sections of the tumors, using the hypoxia marker pimonidazole-hydrochloride to detect hypoxic areas. Tumor vessels in these sections were stained by an endothelial cell marker and perfusion of vessels was visualized by administration of the perfusion marker Hoechst 333342 before harvesting the tumors. The vascular parameters were quantified with an image analysis system. The results show that tumor growth was reduced considerably after suramin treatment. This growth suppression was accompanied by marked changes in vascular architecture. Although the total vascular area and perfused fraction of tumor vessels remained unchanged after suramin treatment, vascular density increased, indicating that more but smaller vessel structures had developed during therapy. These vessel structures were also more homogeneously spread over the tumor area. Control tumors showed extensive areas of hypoxia while in treated tumors hypoxic areas had mostly disappeared. This effect was probably due to the higher density of homogeneously distributed perfused vessel structures in the treated tumors, contributing to an increased oxygenation of the tumor. These observations suggest that suramin therapy can result in marked changes not only in tumor vascularity but also in tumor oxygenation status which may have important consequences for sensitivity of these tumors to other therapies such as radiation treatment.
Article PDF
Similar content being viewed by others
References
Folkman J: Clinical applications of research on angiogenesis. New Engl J Med 333: 1757-1763, 1995
Jain RK: Determinants of tumor blood flow: a review. Cancer Res 48: 2641-2658, 1988
Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465, 1989
Auerbach W, Auerbach R: Angiogenesis inhibition: a review. Pharmac Ther 63: 265-311, 1994
Fan TD, Jaggar R, Bicknell R: Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 16: 57-66, 1995
Gagliardi ART, Hadd H, Collins DC: Inhibition of angiogenesis by suramin. Cancer Res 52: 5073-5075, 1992
Vignon F, Prebois C, Rochefort H: Inhibition of breast cancer growth by suramin. J Natl Cancer Inst 84: 38-42, 1992
Takano S, Gately S, Engelhard H, Tsanaclis AMC, Brem S: Suramin inhibits glioma cell proliferation in vitro and in the brain. J Neuro-Oncol 21: 189-201, 1994
Takano S, Gately S, Neville ME, Herblin W, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding to basic fibroblast growth factor, migration, proliferation and induction of urokinase-type plasminogen activator. Cancer Res 54: 2654-2660, 1994
Schrell UMH, Gauer S, Kiesewetter F, Bickel A, Hren J, Adams EF, Csoka K, Nygren P, Graf W, Pahlman L, Glimelius B, Larsson R: Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients. Br J Cancer 63: 356-360, 1995
Mirza MR, Jakobsen E, Pfeiffer P, Lindebjerg-Clasen B, Bergh J, Rose C: Suramin in non-small cell lung cancer and advanced breast cancer. Acta Oncologica 36: 171-174, 1997
Brem SS, Cotran R, Folkman J: Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 48: 347-356, 1972
Gulledge CJ, Dewhirst MW: Tumor oxygenation: a matter of supply and demand. Anticancer Res 16: 741-750, 1996
Potgens AJG, Lubsen NH, van Altena MC, Schoenmakers JCG, Ruiter DJ, de Waal RMW: Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol 146: 197-209, 1995
Westphal JR, van' t Hullenaar RGM, van der Laak JAWM, Cornelissen IMHA, Schalkwijk LJM, van Muijen GNP, Wesseling P, de Wilde PCM, Ruiter DJ, de Waal RMW:Vascular density in melanoma xenografts correlates with vascular permeability factor expression but not with metastatic potential. Br J Cancer 76: 561-570, 1997
Rijken PFJW, Bernsen HJJA, van der Kogel AJ: Application of an image analysis system for the quantitation of the tumor perfusion and vascularity in human glioma xenografts. Microvasc Res 50: 141-153, 1995
Baghdiguian S, Fantini J: Suramin: a molecule with a broad spectrum of biological and therapeutical properties. Cancer J 10: 31-37, 1997
Westphal M, Ackerman E, Hoppe J, Herrmann HD: Receptors for platelet derived growth factor in human glioma lines and influence of suramin on cell proliferation. J Neuro-Oncol 11: 207-213, 1991
Pesenti E, Sola F, Mongelli N, Grandi M, Spreafico F: Suramin prevents neovascularization and tumor growth through blocking of fibroblast growth factor activity. Br J Cancer 66: 367-372, 1992
Middaugh CR, Mach H, Burke CJ, Volkin DB, Dabora JM, Tsai PK, Bruner MW, Ryan JA, Marfia KE: Nature of the interaction of growth factors with suramin. Biochemistry 31: 9016-9024, 1992
Larsen AK: Suramin, an anticancer drug with unique biological effects. Cancer Chemother Pharmacol 32: 96-98, 1993
Braddock PS, Hu DE, Fan TPD, Stratford IJ, Harris AL, Bicknell R: A structure-activity analysis of antagonism of growth factor and angiogenesis activity of basic fibroblast growth factor by suramin and related polyanions. Br J Cancer 69: 890-898, 1994
Waltenberger J, Mayr U, Frank H, Hombach V: Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. J Mol Cell Cardiol 28: 1523-1529, 1996
Plate KH, Risau W: Angiogenesis in malignant gliomas. Glia 15: 339-347, 1995
Coomber BL: Suramin inhibits C6 glioma-induced angiogenesis in vitro. J Cell Biochem 58: 199-207, 1995
Olson JJ, Polk DM, Reisner A: The efficacy and distribution of suramin in the treatment of the 9L gliosarcoma. Neurosurgery 34: 297-308, 1994
Ramirez LH, Julieron M, Bonnay M, Koscielny S, Zhao Z, Gouyette A, Munck JN: Stimulation of tumor growth in vitro and in vivo by suramin on the VX2 model. Investigational New Drugs 13: 51-53, 1995
Kim KJ, Li B, Winer J, Armanini M, Gillet N, Phillips HS, Ferrara N: Inhibition of VEGF-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993
Taki T, Ohnishi T, Arita N, Hiaga S, Saitoh Y, Izumotot S, Mori K, Hayakawa T: Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: potent inhibition of angiogenesis. J Neuro-Oncol 19: 251-258, 1994
Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci 93: 14765-14770, 1996
Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM: Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56: 1615-1620, 1996
Bernsen HJJA, Rijken PFJW, Peters H, Bakker H, van der Kogel AJ: The effect of the anti-angiogenic agent AGM-1470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice. J Neuro-Oncol 38: 51-57, 1998
Teicher BA, Dupuis N, Kusomoto T, Robinson MF, Liu F, Menon K, Coleman CN: Antiangiogenic agents can increase tumor oxygenation and responses to radiation therapy. Radiat Oncol Invest 2: 269-276, 1995
Kakeji Y, Teicher BA: Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Investigational New Drugs 15: 39-48, 1997
Devineni D, Kleinszanto A, Gallo JM: Uptake of tenozolomide in a rat glioma model in presence or absence of the angiogenesis inhibitor TNP-470. Cancer Res 56: 1983-1987, 1996
Firsching A, Nickel P, Mor AP, Allolio B: Antiproliferative and angiostatic activity of suramine analogues. Cancer Res 55: 4957-4962, 1995
Gagliardi ART, Kassack M, Kreimeyer A, Muller G, Nickel P, Collins DC: Antiangiogenic and antiproliferative activity of suramin analogues. Cancer Chemother Pharmacol 41: 117-124, 1998
Kreimeyer A, Muller G, Kassack M, Nickel P, Gagliardi ART: Sulfanilic acid-, Benzenedisulfonic acid-, and Naphthalenetrisulfonic acid analogues. Arch Pharm Pharm Med Chem 331: 97-103, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bernsen, H., Rijken, P., Peters, J. et al. Suramin Treatment of Human Glioma Xenografts; Effects on Tumor Vasculature and Oxygenation Status. J Neurooncol 44, 129–136 (1999). https://doi.org/10.1023/A:1006363215260
Issue Date:
DOI: https://doi.org/10.1023/A:1006363215260